Last reviewed · How we verify
Hesperidin+Diosmin combination 1000
Hesperidin+Diosmin combination 1000 is a Bioflavonoid combination Small molecule drug developed by Pirogov Russian National Research Medical University. It is currently in Phase 3 development for Chronic venous insufficiency, Hemorrhoids, Lymphedema.
Hesperidin and diosmin are bioflavonoids that improve venous tone and reduce capillary fragility by strengthening blood vessel walls and reducing inflammation.
Hesperidin and diosmin are bioflavonoids that improve venous tone and reduce capillary fragility by strengthening blood vessel walls and reducing inflammation. Used for Chronic venous insufficiency, Hemorrhoids, Lymphedema.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Hesperidin+Diosmin combination 1000 |
|---|---|
| Sponsor | Pirogov Russian National Research Medical University |
| Drug class | Bioflavonoid combination |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This combination works by enhancing vascular endothelial function and reducing inflammatory mediators in the venous system. The flavonoids improve lymphatic drainage and reduce edema by decreasing capillary permeability and increasing venous return. They are commonly used to treat chronic venous insufficiency and related microcirculatory disorders.
Approved indications
- Chronic venous insufficiency
- Hemorrhoids
- Lymphedema
- Microcirculatory disorders
Common side effects
- Gastrointestinal disturbance
- Headache
- Dizziness
Key clinical trials
- Effects of Bioflavanoids on Vascular Wall Remodeling in Patients With Varicose Veins (NA)
- Venoactive Drug Treatment of Pelvic Venous Disorders (PHASE3)
- Clinical Study to Evaluate the Possible Efficacy and Safety of Diosmin and Hesperidin Combined Therapy in Patients With Helicobacter Pylori Infection (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hesperidin+Diosmin combination 1000 CI brief — competitive landscape report
- Hesperidin+Diosmin combination 1000 updates RSS · CI watch RSS
- Pirogov Russian National Research Medical University portfolio CI
Frequently asked questions about Hesperidin+Diosmin combination 1000
What is Hesperidin+Diosmin combination 1000?
How does Hesperidin+Diosmin combination 1000 work?
What is Hesperidin+Diosmin combination 1000 used for?
Who makes Hesperidin+Diosmin combination 1000?
What drug class is Hesperidin+Diosmin combination 1000 in?
What development phase is Hesperidin+Diosmin combination 1000 in?
What are the side effects of Hesperidin+Diosmin combination 1000?
Related
- Drug class: All Bioflavonoid combination drugs
- Manufacturer: Pirogov Russian National Research Medical University — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Chronic venous insufficiency
- Indication: Drugs for Hemorrhoids
- Indication: Drugs for Lymphedema
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing